These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 31639425)

  • 21. Blocking autophagy improves the anti-tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivo.
    Hu X; Shi S; Wang H; Yu X; Wang Q; Jiang S; Ju D; Ye L; Feng M
    Sci Rep; 2017 Jul; 7(1):4559. PubMed ID: 28676644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy.
    Jaiswal BS; Durinck S; Stawiski EW; Yin J; Wang W; Lin E; Moffat J; Martin SE; Modrusan Z; Seshagiri S
    Clin Cancer Res; 2018 Aug; 24(16):4044-4055. PubMed ID: 29760222
    [No Abstract]   [Full Text] [Related]  

  • 23. Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor.
    Zhang Y
    Pharmacol Rev; 2023 Nov; 75(6):1218-1232. PubMed ID: 37339882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concurrent Autophagy Inhibition Overcomes the Resistance of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Human Bladder Cancer Cells.
    Kang M; Lee KH; Lee HS; Jeong CW; Kwak C; Kim HH; Ku JH
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28165387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells.
    Momeny M; Zarrinrad G; Moghaddaskho F; Poursheikhani A; Sankanian G; Zaghal A; Mirshahvaladi S; Esmaeili F; Eyvani H; Barghi F; Sabourinejad Z; Alishahi Z; Yousefi H; Ghasemi R; Dardaei L; Bashash D; Chahardouli B; Dehpour AR; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
    Sci Rep; 2017 Jun; 7(1):4204. PubMed ID: 28646172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
    Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
    Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.
    Wykosky J; Fenton T; Furnari F; Cavenee WK
    Chin J Cancer; 2011 Jan; 30(1):5-12. PubMed ID: 21192840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas.
    Lee TF; Tseng YC; Nguyen PA; Li YC; Ho CC; Wu CW
    Sci Rep; 2018 Jan; 8(1):271. PubMed ID: 29321482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. mAb MDR1-modified chitosan nanoparticles overcome acquired EGFR-TKI resistance through two potential therapeutic targets modulation of MDR1 and autophagy.
    Zheng Y; Su C; Zhao L; Shi Y
    J Nanobiotechnology; 2017 Oct; 15(1):66. PubMed ID: 28978341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disruption of ETV6 leads to TWIST1-dependent progression and resistance to epidermal growth factor receptor tyrosine kinase inhibitors in prostate cancer.
    Tsai YC; Zeng T; Abou-Kheir W; Yeh HL; Yin JJ; Lee YC; Chen WY; Liu YN
    Mol Cancer; 2018 Feb; 17(1):42. PubMed ID: 29455655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting epidermal growth factor receptor and its downstream signaling pathways by natural products: A mechanistic insight.
    Damare R; Engle K; Kumar G
    Phytother Res; 2024 May; 38(5):2406-2447. PubMed ID: 38433568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
    Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
    Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer.
    Kurihara E; Shien K; Torigoe H; Takeda T; Takahashi Y; Ogoshi Y; Yoshioka T; Namba K; Sato H; Suzawa K; Yamamoto H; Soh J; Okazaki M; Shien T; Tomida S; Toyooka S
    Anticancer Res; 2019 Apr; 39(4):1767-1775. PubMed ID: 30952716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The quest to overcome resistance to EGFR-targeted therapies in cancer.
    Chong CR; Jänne PA
    Nat Med; 2013 Nov; 19(11):1389-400. PubMed ID: 24202392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
    Stewart EL; Mascaux C; Pham NA; Sakashita S; Sykes J; Kim L; Yanagawa N; Allo G; Ishizawa K; Wang D; Zhu CQ; Li M; Ng C; Liu N; Pintilie M; Martin P; John T; Jurisica I; Leighl NB; Neel BG; Waddell TK; Shepherd FA; Liu G; Tsao MS
    J Clin Oncol; 2015 Aug; 33(22):2472-80. PubMed ID: 26124487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 6-Phosphogluconate dehydrogenase fuels multiple aspects of cancer cells: From cancer initiation to metastasis and chemoresistance.
    Sarfraz I; Rasul A; Hussain G; Shah MA; Zahoor AF; Asrar M; Selamoglu Z; Ji XY; Adem Ş; Sarker SD
    Biofactors; 2020 Jul; 46(4):550-562. PubMed ID: 32039535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of Acquired Resistance towards EGFR Inhibitor Gefitinib in a Patient-Derived Xenograft Model of Non-Small Cell Lung Cancer and Subsequent Molecular Characterization.
    Schueler J; Tschuch C; Klingner K; Bug D; Peille AL; de Koning L; Oswald E; Klett H; Sommergruber W
    Cells; 2019 Jul; 8(7):. PubMed ID: 31323891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells.
    Kinehara Y; Nagatomo I; Koyama S; Ito D; Nojima S; Kurebayashi R; Nakanishi Y; Suga Y; Nishijima-Futami Y; Osa A; Nakatani T; Kato Y; Nishide M; Hayama Y; Higashiguchi M; Morimura O; Miyake K; Kang S; Minami T; Hirata H; Iwahori K; Takimoto T; Takamatsu H; Takeda Y; Hosen N; Hoshino S; Shintani Y; Okumura M; Kumagai T; Nishino K; Imamura F; Nakatsuka SI; Kijima T; Kida H; Kumanogoh A
    JCI Insight; 2018 Dec; 3(24):. PubMed ID: 30568033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy.
    To KKW; Wu WKK; Loong HHF
    Eur J Pharmacol; 2018 Mar; 823():19-26. PubMed ID: 29378193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.